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Abstract
Diabetic nephropathy is a complex and poorly understood disease process, and our current treatment options are limited. It
remains critical, then, to identify novel therapeutic targets. Recently, a developmental protein and one of the bone
morphogenetic protein antagonists, Gremlin, has emerged as a novel modulator of diabetic nephropathy. The high
expression and strong co-localization with transforming growth factor- b1 in diabetic kidneys suggests a role for Gremlin in
the pathogenesis of diabetic nephropathy. We have constructed a gremlin siRNA plasmid and have examined the effect of
Gremlin inhibition on the progression of diabetic nephropathy in a mouse model. CD-1 mice underwent uninephrectomy
and STZ treatment prior to receiving weekly injections of the plasmid. Inhibition of Gremlin alleviated proteinuria and renal
collagen IV accumulation 12 weeks after the STZ injection and inhibited renal cell proliferation and apoptosis. In vitro
experiments, using mouse mesangial cells, revealed that the transfect ion of gremlin siRNA plasmid reversed high glucose
induced abnormalities, such as increased cell proliferation and apoptosis and increased collagen IV production. The
decreased matrix metalloprotease level was partially normalized by transfection with gremlin siRNA plasmid. Additionally,
we observed recovery of bone morphogenetic protein-7 signaling activity, evidenced by increases in phosphorylated Smad
5 protein levels. We conclude that inhibition of Gremlin exerts beneficial effects on the diabetic kidney mainly through
maintenance of BMP-7 activity and that Gremlin may serve as a novel therapeutic target in the management of diabetic
nephropathy.
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Introduction
Diabetic nephropathy (DN) is the leading cause of end-stage
renal disease and about 20% to 40% of patients with diabetes
ultimately develop diabetic nephropathy[1,2]. Specific therapies to
reverse or inhibit the progression of diabetic nephropathy to
advanced stages are not available and current treatment strategies
are limited to management of blood glucose levels and control of
hypertension[3,4]. Diabetic nephropathy is characterized by
various pathological features, such as renal cell proliferation and
apoptosis, mesangial expansion and sclerosis, glomerular basement
membrane thickening and the subsequent development of
tubulointerstitial fibrosis[2]. Hyperglycemia is the major factor
precipitating renal injury in this setting[5]. However, the
downstream signaling pathways which influence this process are
not fully defined. One known mediator in the development of both
glomerulosclerosis and tubulointerstitial fibrosis is transforming
growth factor- b1 (TGF-b1)[6]; however, because of its pleiotropic
actions, TGF-b may not be an ideal therapeutic target. Recently, a
role for the re-activation of developmental programs in DN has
been recognized[7]. Increased gene expression of such molecules
as connective tissue growth factor (CTGF), vascular endothelial
growth factor (VEGF), bone morphogenetic proteins (BMPs) and
gremlin, a BMP antagonist, supports the notion that ontogenic
processes are operative in the development of DN[6,8,9,10].
Gremlin is a 184-amino acid protein which is present in both
soluble and cell-associated forms. It is highly conserved and is a
member of the structural cysteine knot superfamily. Functionally,
Gremlin plays an important role in development and belongs to a
novel family of bone morphogenetic protein (BMP) antagonists
that include the head inducing factor Cerberus and the tumor
suppressor DAN[11]. Under basal conditions, Gremlin is present
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11709at relatively low levels in the adult kidney[12,13]. However, it is
highly expressed in biopsy specimens from patients with diabetic
nephropathy, where it is predominantly observed in areas of
tubulointerstitial fibrosis and where it co-localizes with TGF-b1
expression[12,13]. In addition, Gremlin mRNA levels correlate
directly with elevated serum creatinine levels and tubulointerstitial
fibrosis scores in patients with DN[12]. Further, Gremlin
expression is enhanced in mesangial cells cultured under high
glucose conditions and in those exposed to cyclic mechanical strain
and transforming growth factor-b (TGF-b)[7]. Collectively, these
data suggest a role for Gremlin in the pathogenesis of
tubulointerstitial fibrosis in DN. Thus, we hypothesize that
Gremlin may serve as a therapeutic target in the management
of this disease. To explore this possibility, we utilized a mouse
model of diabetic nephropathy (uninephrectomy and streptozot-
ocin (STZ) treatment) to examine the effect of siRNA-induced
Gremlin inhibition in vivo on the progression of renal pathology.
Results
Gremlin Expression in Mouse Kidney is Inhibited by
Gremlin siRNA Plasmid
As seen in Figure 1A, Gremlin protein expression in the STZ-
treated group was about 1.5-fold greater than in the non-diabetic
control mice (N). Treatment with gremlin siRNA plasmid
significantly inhibited Gremlin expression induced by diabetic
conditions (Gremlin-si). Immunostaining (Figure 1B) revealed
that, in the non-diabetic control group, Gremlin expression was
predominantly detected in glomeruli, while signal was barely seen
in tubules and interstitial areas. In the STZ group, Gremlin was
highly expressed in glomeruli and also in interstitial areas and part
of tubules at week-2. In the Gremlin-si group, Gremlin expression
was significantly weaker in both glomeruli and tubular interstitial
areas, indicating a successful inhibition of Gremlin expression by
gremlin siRNA plasmid (Figure 1B).
Treatment with Gremlin siRNA Plasmid Alleviates
Proteinuria, Serum Creatinine Elevation and Renal
Hypertrophy
At week-12, the urinary protein level was dramatically higher in
the STZ group compared to control. Gremlin siRNA plasmid
treatment significantly reduced proteinuria (Figure 2A). The
serum creatinine was also increased in the STZ group compared
with that of control, and treatment with gremlin siRNA plasmid
significantly reduced the high level of serum creatinine in diabetic
mice (Figure 2B). In addition, the glomerular and tubular
diameters and cell numbers significantly increased in the STZ
group compared with those of the control mice, while the
treatment with gremlin siRNA plasmid alleviated these changes
(Figure 2, C, D, E & F). We further investigated the protective
effects of treatment with gremlin siRNA plasmid on diabetic
nephropathy by assessment of the histopathological changes and
collagen type IV accumulation at week-12. Diabetic mice in the
STZ group exhibited significant tubular and glomerular hyper-
trophy, widened mesangial areas, as well as increased collagen
type IV expression compared with the non-diabetic control group.
Treatment with gremlin siRNA plasmid was associated with a
significant reduction in renal hypertrophy, mesangial areas and
accumulation of collagen type IV (Figure 2G, H). These data
demonstrate that gremlin siRNA plasmid delivery significantly
inhibited glomerular and tubular hypertrophy in diabetic kidneys
from week 1 to week 12, alleviated proteinuria and displayed a
protective effect on renal function at week 12.
Delivery of Gremlin siRNA Plasmid Inhibits Renal Cell
Proliferation and Apoptosis in Diabetic Mice
Proliferation of kidney cells was evaluated with PCNA staining.
PCNA positive cells were occasionally seen in the non-diabetic
control group and were significantly increased in the tubules and
glomeruli of the STZ group at week-1 and -2. Delivery of gremlin
siRNA plasmid reduced the numbers of PCNA positive cells. By
week-12, the numbers of PCNA positive cells returned to basal
levels in the STZ and Gremlin-si groups, and there were no
differences among the three groups (Figure 3, A, B & C). The
kidney tissue of the diabetic mice at week-2 was double stained with
antibodies against PCNA and Gremlin. PCNA positive signals were
often seen in cells with intense Gremlin expression, both in
glomeruli and tubules, as well as in the renal medulla (Figure 3D).
No apparent apoptotic cells were seen in the three groups at week-1
and week-2; at week-12, cell apoptosis was barely seen in the non-
diabetic control group and in glomeruli from the STZ group.
However, there was clustering of apoptotic cells in the tubules of the
STZ group. Treatment with gremlin siRNA plasmid significantly
reduced the number of apoptotic cells (Figure 3E, F).
Expression of BMP-7 in Diabetic Kidney is not directly
Regulated by Gremlin
As shown in Figure 4, expression of BMP-7 in kidney cortical
homogenates from the STZ group markedly decreased compared
to that of the control group at week-12. No obvious effect of
gremlin siRNA plasmid on BMP-7 expression in the diabetic
kidney was seen, which indicated that BMP-7 expression in the
kidneys of STZ-induced diabetic rats may not be directly regulated
by Gremlin.
Transfection with Gremlin siRNA Plasmid Normalizes Cell
Proliferation Induced by Exposure to High Glucose Levels
Mouse mesangial cells were transfected with control or gremlin
siRNA plasmid and then assessed for cell proliferation by PCNA
staining after high glucose (HG) stimulation. Gremlin protein
expression was efficiently inhibited by transfection with gremlin
siRNA plasmid, as demonstrated by Western blot analysis of cell
extracts (Figure 5A) and by ELISA using culture medium
(Figure 5B). As shown in Figure 5C, the number of proliferative
cells significantly increased in the HG group (2165%) and the HG
and control plasmid group (2064%). Transfection with gremlin
siRNA plasmid into MCs significantly inhibited the HG-induced
cell proliferation (1264%).
Transfection with Gremlin siRNA Plasmid Reduces
Collagen Type IV Accumulation in Cells Exposed to High
Glucose
To evaluate the influence of Gremlin inhibition on collagen type
IV synthesis and possible mechanisms of interaction, cultured
mouse mesangial cells were again transfected with control or
gremlin siRNA plasmid and then subjected to stimulation with
high glucose. Collagen type IV levels in the culture medium were
determined by radio-immunoassay, and cells were collected for
Western blot analysis of TGF-b, and matrix metalloprotease-2
(MMP-2) activity in culture medium was determined by
zymography (Figure 6). Significant accumulation of collagen
type IV in the culture medium was seen in the HG and HG+V
groups, while gremlin siRNA plasmid transfection significantly
reduced the collagen type IV accumulation (Figure 6A). TGF-b
expression significantly increased under high glucose conditions,
and no obvious effect was observed after gremlin siRNA
transfection. On the other hand, MMP-2 activity was significantly
Gremlin and Diabetic Kidney
PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11709Figure1.Deliveryof gremlinsiRNAplasmid into diabeticCD-1 micepost-uninephrectomy. (A) Gremlin protein expression by western blotting
in whole-kidney homogenates at different time points after injection of pBAsi mU6 Neo control vector or pBAsi mU6 Neo gremlin siRNA plasmid,
respectively. Compared to those treated with pBAsi mU6 Neo plasmid (STZ group), animals administered pBAsi mU6 Neo gremlin siRNA plasmid (Gremlin
siRNA group) show low expression of Gremlin in the kidneys. (B) Immunostaining of kidney sections shows the localization of Gremlin protein after the
delivery of plasmids. Marked Gremlin expression is observed in both glomeruli and tubules in the STZ group, which is significantly inhibited by the delivery
of gremlin siRNA plasmid. (* p,0.01 vs. non-diabetic control group; #p,0.05 vs. STZ group). Scale bars, 100 mm. N=6 mice per group.
doi:10.1371/journal.pone.0011709.g001
Gremlin and Diabetic Kidney
PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11709Gremlin and Diabetic Kidney
PLoS ONE | www.plosone.org 4 July 2010 | Volume 5 | Issue 7 | e11709decreased in the HG and HG+V groups compared to control. The
glucose-induced suppression of MMP-2 activity was inhibited by
transfection with gremlin siRNA plasmid (Figure 6B).
Gremlin Interacts with BMP-7 and Regulates BMP-7
Activity in Mesangial Cells
To investigate the mechanism by which the inhibition of gremlin
expression mediates its renal protective effects, the expression and
activity of BMP-7 was examined in mouse mesangial cells cultured
under HG conditions. Co-immunoprecipitation revealed a physical
interaction between BMP-7 and Gremlin (Figure 7A). Incubation of
cultured cells under HG conditions over 48 hours revealed a gradual
i n c r e a s ei nG r e m l i ne x p r e s s i o nw i t ha s s o c i a t e dd e c r e a s ei nB M P - 7a t
both the mRNA level and protein level (Figure 7B & C). Similarly
the level of phosphorylated Smad-5, a marker of BMP-7 activity,
significantly and gradually went down while total Smad-5 protein
levels remained constant (Figure 7C). No significant changes in
BMP-7 expression were seen after transfection of cells with gremlin
siRNA plasmid (Figure 8A, B, C & E), whereas the decrease in
phosphorylation of Smad-5 was prevented by gremlin siRNA plasmid
transfection (Figure 8C & G). These results suggest that the
protective effects of siRNA-induced inhibition of gremlin expression
on DN were, at least partially, through the recovery of BMP-7 activity.
Discussion
The molecular pathogenesis of diabetic nephropathy has not
been fully characterized, and novel mediators of the disease are
still being described. The re-activation of developmental programs
in DN has shed light on novel pathways influencing the disease
and suggests new potential therapeutic targets. Bone morphoge-
netic proteins, active in development, are homodimeric members
of the TGF-bsuperfamily of cysteine-knot cytokines[14,15]. The
TGF-b superfamily comprises over twenty BMPs, of which BMP-7
is the most prominent member involved in renal development and
disease. In the adult life, BMP-7 is primarily expressed in kidney
tubules, as well as glomeruli[16,17,18]. Loss of endogenous BMP-
7 expression occurs in diabetic rats and is associated with
profibrotic activity[19,20]. In the streptozotocin diabetic model
BMP-7 is reduced by 50% at 15 weeks and continues to decline
further to 10% by 30 weeks[21]. In cultured tubular cells, TGF-
bdecreases BMP-7 expression, which suggests that a rise in tubular
TGF-b levels during the evolution of diabetic nephropathy
contributes causally to the loss of BMP7 and BMP7 type I and
II receptors. Morrissey and associates showed that exogenously
administered recombinant human (rh) BMP-7 may even resolve,
at least partially, glomerular and interstitial fibrosis in experimen-
tal diabetic nephropathy. BMP-7 activity in the kidney is not only
determined by availability of BMP-7 itself, but also by a balance of
agonists, such as Kielin/chordin-like protein (KCP) or BMP
receptors, and antagonists, such as gremlin, noggin, or uterine
sensitization-associated gene-1 (USAG-1), that prohibit BMPs
from binding to their cognate receptors[22]. Among three BMP
antagonists, only gremlin increases in diabetic rat kidneys[19].
Here we propose that inhibition of Gremlin may induce
therapeutic effects on the diabetic kidney by allowing the efficient
binding of endogenous BMP-7 to receptors without inhibition.
In the current study, diabetes was induced in CD-1 mice and
siRNA plasmid was transferred weekly into the diabetic mice to
inhibit Gremlin expression. AMDCC investigators indicate signif-
icant diversity among individual CD-1 mice in the levels of
albuminuria with low dose STZ diabetes (http://www.amdcc.org/
shared/showFile.aspx?doctypeid=7&docid=530), but high dose
STZ results in severe diabetic nephropathy in CD-1 mice, which
was reported to mimic human diabetic nephropathy in histopath-
ologic lesions and renal function[23], so we used high dose STZ to
induce diabetes in CD-1 mice, similar levels in renal function
parameters and histological changes were seen in animals withinthe
same experimental group. Our data demonstrate that administra-
tion of gremlin siRNA plasmid to diabetic mice alleviated renal
hypertrophy, cell proliferation and apoptosis, and subsequently
suppressed collagen type IV accumulation and mesangial expan-
sion, indicating beneficial effects of Gremlin inhibition on diabetic
nephropathy. A significant reduction in BMP-7 expression at the
late stage of diabetic nephropathy has been reported[20]. Based
upon our data, the expression level of BMP-7 dramatically dropped
to half of the control level by week 12. Gremlin siRNA treatment
showed no effect on the reduced expression level of BMP-7 in
diabetic kidneys. However, a physical interaction between BMP-7
and Gremlin was demonstrated by immunoprecipitation, and
phosphorylated Smad-5, a marker of BMP-7 activity, was up-
regulated by gremlin siRNA plasmid transfection. BMPs binding to
their receptors activate mothers against decapentaplegic (Smad)
signaling, which is revealed by the phosphorylation of
Smads[24,25]. Smad 1, 5 and 8 are receptor regulated Smads (R-
Smads) that can be activated by BMPs. Smad5 was found to be the
preferred BMP-7-induced receptor-activated Smad signal in
kidney[26]. Loss of BMP-7 signaling activity, as illustrated by lower
phosphorylated Smad 5 protein level, was observed in experimental
diabetic nephropathy[27]. Our results from mesangial cells cultured
under high glucose conditions, demonstrate that a gradual increase
in Gremlin protein levels from 6 h to 48 h after HG stimulation is
associated with decreasing levels of phosphorylated Smad-5.
Transfection of these cells with gremlin siRNA plasmid resulted in
significantly increased levels of phosphorylated Smad-5, whereas,
there was no significant increase of BMP7 level after trasfection of
gremlin siRNA plasmid. Taken together, our in vivo and in vitro data,
as well as the functional studies relating to BMP-7 and gremlin
reported in the literature, support a model in which the major
mechanism of therapeutic action of gremlin inhibition on DN is
related to the recovery of BMP-7 activity. Firstly, BMP-7 is involved
in ameliorating renal damage due to mesangial proliferation by
suppression of mesangial cell mitosis via Smad1, 25, 28
signaling[28]. BMP-7 is also able to prevent metanephric
mesenchymal cells and renal epithelial cells from undergoing
apoptosis, thereby preserving renal function[29,30]. From our
study, the inhibition of gremlin expression was able to normalize
renal cell growth, including HG-induced proliferation and apopto-
Figure 2. The effects of gremlin siRNA plasmid delivery on diabetic nephropathy in diabetic mice post-uninephrectomy. (A)
Increased spot urinary protein levels and (B) serum creatinine in STZ-induced diabetic mice treated with pBAsi mU6 Neo control plasmid (STZ)
compared with nondiabetic control animals (N). The effect is decreased by treatment of diabetic animals with pBAsi mU6 Neo gremlin siRNA plasmid
(Gremlin-si). (C, D) Increase in glomerular and tubular diameters at week 2 and week 12 is ameliorated by treatment with gremlin siRNA plasmid. (E,
F) Increases in cell numbers in both glomeruli and tubules at week 2 and week 12 are significantly reduced in the Gremlin siRNA group. (G) PAS
staining of kidney tissues shows glomerular and tubular hypertrophy and mesangial matrix accumulation in the STZ group 12 weeks after STZ
injection. Treatment with gremlin siRNA plasmid prevents these pathological changes. (H) Collagen type IV expression in the kidneys at week 12.
High expression of collagen IV is seen in diabetic kidney and the treatment of gremlin siRNA plasmid significantly down-regulated the accumulation
of collagen IV. (* p,0.05, vs. non-diabetic control group,
# p,0.05, vs. STZ group). Scale bars, 100 mm( G, H). N=6 mice per group.
doi:10.1371/journal.pone.0011709.g002
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partially resulting from cell proliferation, acts as a pacemaker for
subsequent irreversible structural changes, such as glomeruloscle-
rosis and tubulointerstitial fibrosis[31]. Secondly, maintenance of
BMP-7 activity by inhibition of Gremlin expression may result in
blockade of extracellular matrix (ECM) accumulation. It was
reported that BMP-7 could reduce TGF-b-induced ECM protein
accumulation in cultured mesangial cells by maintaining the levels
and activity of MMP2, partially through prevention of TGF-b-
dependent upregulation of PAI-1[31,32,33]. Our data showed that
treatment with gremlin siRNA plasmid resulted in a significant
reduction in mesangial areas and accumulation of collagen type IV
in diabetic mice, and the reduced matrix metalloprotease (MMP-2)
level inmesangial cells cultured under HGconditions wasenhanced
by transfection with gremlin siRNA plasmid.
A specific question should be addressed whether Gremlin has
BMP-7-independent effects on the pathogenesis of diabetic nephrop-
athy. As shown in Figure 3D, the proliferative activity of mesangial
cellsisassociatedwiththeexpressionlevelofGremlin.Itwasreported
that Gremlin can increase DNA synthesis and cell counts and
accelerate cell cycle progression of vascular smooth muscle cells
(VSMC) through mechanisms that include p27(kip1) down-regula-
tion[15]. Gremlin was also found overexpressed in various human
tumors and widely expressed by cancer-associated stromal cells, and
can promote tumor cell proliferation [34,35], suggesting the ability of
proliferation stimulation. Thus it is possible that Gremlin regulates
cell growth via a BMP-7-independent pathway.
Overexpression of Gremlin in diabetic kidneys suggests a role for
the re-activation of developmental programs in DN. In addition to
Gremlin, some other developmental genes, such as FMN1[36], a
gene with a Gremlin transcriptional enhancer within the 39 end of
its locus should be considered as well. While Gremlin expression
may be regulated by FMN1, knockdown of Gremlin by siRNA
plasmid might not affect the expression and function of FMN1.To
date, no evidence suggests that Gremlin regulates Fmn1. Thus
FMN1 wasnot measuredinthe currentstudy.Basedonthe fact that
both Gremlin and FMN1 have important implications for renal
system, and the role of FMN1 in gremlin transcriptional regulation,
Figure 3. Cell proliferation and apoptosis in diabetic mouse kidneys. (A) Detection of proliferating cell nuclear antigen (PCNA) by
immunoperoxidase staining, in the kidneys of non-diabetic control mice (N), streptozotocin-induced diabetic mice treated with pBAsi mU6 Neo
control plasmid (STZ) or pBAsi mU6 Neo gremlin siRNA plasmid (Gremlin siRNA). (B and C) PCNA positive cells in kidneys from the STZ group
dramatically increase at week-1 and -2, and pBAsi mU6 Neo gremlin siRNA plasmid treatment significantly reduces PCNA positive cells both in
glomeruli and tubules. Proliferating cells are barely seen in all three groups at week 12. (D) Co-immunostaining of diabetic kidney sections with
antibodies against PCNA and Gremlin. Intensive Gremlin expression is often seen in the cells with PCNA positive signal. (E, F) In situ TUNEL assay.
Apoptotic cells are observed predominantly in tubules in the STZ group at week-12. The number of apoptotic cells is significantly reduced by pBAsi
mU6 Neo gremlin siRNA plasmid treatment. (* p,0.01 vs. non-diabetic control group, # p,0.01 vs. STZ group). Scale bars, 100 mm( A, B and E), and
10 mm( D). N=6 mice per group.
doi:10.1371/journal.pone.0011709.g003
Figure 4. BMP-7 expression in diabetic kidneys assessed by Western blotting. Compared with non-diabetic control mice (N), mice in the
STZ group display similar BMP-7 kidney expression levels at week-1 and week-2. The BMP-7 expression in the STZ group gradually decreased to a
significantly lower level at week-12. No significant effect is seen on the expression of BMP-7 in diabetic kidneys by the treatment with gremlin siRNA
plasmid. (* p,0.05). N=6 mice per group.
doi:10.1371/journal.pone.0011709.g004
Gremlin and Diabetic Kidney
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associated with diabetic nephropathy in the future study.
In summary, in addition to advancing our knowledge of the
pathophysiology of diabetic nephropathy, our data using in vivo
delivery of gremlin siRNA plasmid has special relevance to new
therapies that target Gremlin. Our findings suggest a role for
siRNA-mediated gremlin inhibition in protecting the kidney from
the development and progression of diabetic nephropathy, and
support the further study of Gremlin as a therapeutic target in the
treatment of DN. This work, then, has important implications for
the future development of Gremlin inhibitory strategies.
Materials and Methods
Animal Model and Experimental Design
12-week-old male CD-1 mice (Charles River Laboratories,
Vitalriver, Beijing, China) underwent uninephrectomy and were
subsequently divided into three groups: a non-diabetic control
group (N), a diabetic group administered a pBAsi mU6 Neo
control plasmid (STZ), and a diabetic group administered a pBAsi
mU6 Neo gremlin siRNA plasmid (Takara Bio Inc, Shiga, Japan)
(Gremlin-si) (N=18 per group). To induce diabetes, animals
received a single dose of 150 mg/kg streptozotocin (Sigma, St.
Louis, MO) in citrate buffer at pH 4.6 intravenously, two weeks
after uninephrectomy. Hyperglycemia (.15 mmol/L) was con-
firmed 3 days after STZ administration. Plasmids were then
delivered weekly by tail vein injection using the TransIT-EE
Hydrodynamic Delivery System (Mirus Bio, Madison, USA).
Animals were sacrificed at week-1, week-2 and week-12. At each
time point, urine and blood samples were collected, and kidney
tissues were harvested. All animal procedures were in accordance
with the Guide for Care and Use of Laboratory Animals at the
Department of Animal Resources, Hebei Medical University; the
ethics committee approved this study (approval number: A-0709).
Generation of pBAsi mU6 Neo Gremlin siRNA Plasmid
Three gremlin siRNA plasmids were constructed based on the
U6 siRNA expression vector, pBAsi mU6 Neo (Takara, Mie,
Japan), which includes a mouse U6 promoter and an amp-
resistance gene. The following sets of sense and antisense
Figure 5. Cell proliferation in human mesangial cells cultured under high glucose conditions. Human mesangial cells were cultured in
RPMI 1640 containing normal glucose (100 mg/dl D-glucose; NG) and high glucose (300 mg/dl D-glucose; HG). Cells under HG conditions were
transfected with pBAsi mU6 Neo control plasmid (HG+V) or pBAsi mU6 Neo gremlin siRNA plasmid (HG+gremlin si) 12 hours before the glucose
stimulation. Cell proliferation was examined by PCNA staining 12 hours after glucose stimulation. Gremlin expression is examined in human
mesangial cells by Western blot (A); the secreted Gremlin in culture medium is observed by ELISA (B). The HG stimulated Gremlin expression in
human mesangial cells is successfully inhibited by the transfection of pBAsi mU6 Neo gremlin siRNA plasmid. (C) High glucose-induced cell
proliferation is inhibited in the HG+gremlin si group. (* p,0.05, ** p,0.01). Six independent experiments were repeated.
doi:10.1371/journal.pone.0011709.g005
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oligo 1: 59-GATCCGCACATCCGAAAGGAGGAATAGTG-
CTCCTGGTTGTTCCTCCTTTCGGATGTGCTTTTTTA-
39, antisense oligo 1: 59-AGCTTAAAAAAGCACATCCGA-
AAGGAGGAACAACCAGGAGCACTATTCCTCCTTTCG-
GATGTGCG-39;s e n s eo l i g o2 :5 9-GATCCGCCATCGA-
CTTGGATTAAGTTAGTGCTCCTGGTTGACTTAATCC-
AAGTCGATGGCTTTTTTA- 39, antisense oligo 2: 59-AGCT-
TAAAAAAGCCATCGACTTGGATTAAGTCAACCAGGA -
GCACTAACTTAATCCAAGTCGATGGCG- 39;s e n s eo l i g o
3: 59-GATCCGGATTTCACTTGAGAATGATAGTGCTCC-
TGGTTGTCATTCTCAAGTGAAATCCTTTTTTA- 39, an-
tisense oligo 3: 59-AGCTTAAAAAAGGATTTCACTTGAGA-
ATGACAACCAGGAGCACTATCATTCTCAAGTGAAATC-
CG- 39.
In vivo Delivery Method
To test the efficiencyofthethree pBAsimU6Neogremlin siRNA
plasmids, mouse mesangial cells cultured under high-glucose
conditions were transfected with the plasmids, and the plasmids
were also delivered into diabetic mice in vivo. Gremlin expression
was evaluated by Western blot and immunohistochemistry. The
mosteffective plasmid (oligo 1) was used for the study. Each diabetic
animalreceived30 mg ofendotoxin-freeplasmidDNAsuspended in
2 ml of the TransIT-EE Hydrodynamic buffer weekly by tail vein
injection according to the manufacturer’s protocol.
Light Microscopy
Kidneys were fixed in 4% paraformaldehyde and embedded in
paraffin for light microscopy and immunohistochemistry. 2 mm
sections were stained with Hematoxylin and Eosin (HE) and
periodic acid-Schiff (PAS). The number of cells and diameter of
glomeruli and tubules were quantitatively analyzed with the TD
2000 image pattern analysis system. Fifty glomeruli and 100
tubules for each animal were evaluated.
In vitro Experiments
Mouse mesangial cells (MCs) were purchased from the American
Type Culture Collection (Manassas, USA). Cells were grown in
RPMI 1640 (Gibco) containing 5% FBS, penicillin (100 U/ml),
streptomycin (100 mg/ml), and HEPES (14 mM) at 37uCa n d5 %
CO2 -95% air. 2610
6 cells perwell in6-wellculture plates or 2610
5
cells per each Lab-Tek16 chamber slide (Nalge Nunc International)
were cultured without antibiotics for 24 hours. Then cells were
transfected with pBAsi mU6 Neo gremlin siRNA plasmid or pBAsi
mU6 Neo plasmid using lipofectamine 2000 reagent (Invitrogen).
Figure 6. Collagen type IVand TGF-bexpression and MMP-2 activity in mouse mesangial cells cultured under high glucose conditions.
Mouse mesangial cells were cultured in RPMI 1640 and transfected with pBAsi mU6 Neo or pBAsi mU6 Neo gremlin siRNA plasmid as described in the
methods.CulturemediumwascollectedformeasurementofcollagentypeIVconcentration byradio-immunoassay,andcellsweresubjectedtoWestern
blot analysis to determine MMP-2 and TGF-bexpression levels 48 hours after glucose stimulation. (A) Increased collagen type IV accumulation is
observed in the HG group, and gremlin siRNA plasmid transfection significantly inhibits collagen type IV secretion. (B) Compared to the normal glucose
controlgroup(NG),TGF-bexpressionissignificantlyincreasedunderhighglucoseconditions,andtheHGstimulatedTGF-bexpressionremainsthesame
after gremlin siRNA transfection. (C) Compared with the NG group, MMP-2 activity in culture medium is significantly decreased in the HG and HG+V
groups, and this is prevented by transfection with gremlin siRNA plasmid. (* p,0.05, ** p,0.01). Six independent experiments were repeated.
doi:10.1371/journal.pone.0011709.g006
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high glucose (HG; 25 mM) or normal glucose (NG; 2.8 mM) for up
to 48 hours. Cells in 6-well culture plates were collected for protein
extraction. Cells on Lab-Tek16 chamber slides were fixed in 4%
paraformaldehyde for immunochemistry, and culture medium was
collected for Collagen IV measurement.
RT-PCR
Total RNA was purified from mIMCD-3 cells with QIAzol
Reagent (Qiagen). cDNA was synthesized from 2.5 g total RNA.
The primer sequences are as follows: gremlin forward: 59-
GACAAGGCTCAGCACAATGA- 39, gremlin reverse: 59-
AACTTCTTGGGCTTGCAGAA- 39, BMP-7 forward: 59-
Figure 7. Gremlin interacts with BMP-7 and regulates BMP-7 activity in mesangial cells. Mouse mesangial cells were cultured in RPMI
1640 and collected 6 h, 12 h, 24 h and 48 h after HG stimulation. (A) Co-immunoprecipitation demonstrates an interaction between BMP-7 and
Gremlin in mesangial cells. (B) mRNA levels of gremlin and BMP-7 are detected by RT-PCR. After HG stimulation, a significant increase in Gremlin
mRNA level is observed after 6 hours incubation in high glucose, and the expression gradually increases with the culture duration. (C) The expression
of BMP-7 mRNA dramatically decreases 48 hours later. Accordingly, increased Gremlin protein levels are observed in the cultured cells. Corresponding
to a decrease in the protein level of BMP-7, the level of Smad-5 remained constant, whereas phosphorylated Smad-5 significantly and gradually
decreases from 12 h to 48 h (* p,0.05, ** p,0.01 vs. the value of NG group).
doi:10.1371/journal.pone.0011709.g007
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PLoS ONE | www.plosone.org 10 July 2010 | Volume 5 | Issue 7 | e11709Figure 8. BMP-7 activity in mouse mesangial cells transfected with gremlin siRNA plasmid. Mouse mesangial cells were transfected with
pBAsi mU6 Neo or pBAsi mU6 Neo gremlin siRNA plasmid and stimulated with NG and HG. Cells were collected 48 hours after HG stimulation and
subjected to RT-PCR and Western blot. BMP-7 mRNA level was found decreased after gremlin siRNA transfection (A&B ). The protein levels of BMP-7
and Phos-Smad-5/Smad-5 decreased after 48 hours incubation with high glucose. Transfection with gremlin siRNA plasmid significantly increased the
Phos-Smad-5/Smad-5 level (* p,0.01), whereas levels of BMP-7 and Smad-5 remained similar (C, D, E, F, and G). Six independent experiments were
repeated.
doi:10.1371/journal.pone.0011709.g008
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GCTCAGGAGAGGTTGGTCTG- 39, GAPDH forward: 59-
CCCACTAACATCAAATGGGG - 39, GAPDH reverse: 59-
ATCCACAGTCTTCTG GGTGG - 39. The relative abundance
of mRNAs was standardized with GAPDH mRNA as the control.
Western Blotting
30 mg of protein from each sample was subjected to SDS/
PAGE under reducing conditions, and the gel proteins were
electroblotted onto Hybond PVDF membrane (Amersham).
Membranes were incubated with rabbit polyclonal anti- Gremlin,
BMP-7, BMP-2, Smad5, Pho-Smad5, and TGF-beta antibodies
(1:500,1:1000, Santa Cruz) overnight, and then the membranes
were incubated with anti-rabbit IgG conjugated to horseradish
peroxidase (1:20,000) at 37uC for 1 hour. After washing with
PBST, the blots were incubated with ECLH Plus Western Blotting
Detection Reagent (Amersham) and then exposed to X-ray film.
Immunohistochemistry and Immunocytochemistry
The paraformaldehyde-fixed and paraffin-embedded kidney
tissues were cut into sections of 4 mm thickness. After deparaffi-
nization and rehydration, the slides were incubated with 3% H2O2
for 15 minutes at room temperature to block any intrinsic
peroxidase activity and with 20% normal goat serum for 2 hours
at 37uC to prevent non-specific binding of serum proteins. For
immunohistochemistry, the tissues were then incubated sequen-
tially with antibodies against PCNA or Gremlin (1:100 or 1:50
respectively, Santa Cruz) for 1 hour at 37uC, biotinylated anti-
rabbit or anti-mouse IgG (1:100; Gibco-BRL) for 20 min and
streptavidin-peroxidase conjugate for 20 min. For immune-double
staining, the tissues were incubated with a mixture of mouse anti-
PCNA (1:50) and rabbit anti-Gremlin (1:50). Anti-PCNA
antibodies were detected using goat anti-Mouse IgG-HRP with
DAB reagent to produce brown staining. Anti-Gremlin antibodies
were detected using goat anti-Rabbit IgG-AP with Fast-Red
reagent to produce red staining.
Gelatin Zymography
MMP-2 activity was determined by zymography by measuring
gelatinolytic activity in culture media. Briefly, culture medium
sampled after the desired incubation was centrifuged by 2000 rpm
for 10 min. Protein concentration was determined by Bradford
method. 40 mg of protein from each sample was applied to a 10%
zymography gel and electrophoresed constantly at 90 mA for
60 min. Gels were firstly washed twice with washing buffer (2.5%
Triton X-100,50 mmol/L Tris –HCl, 5 mmol/L CaCl2, 1 mmol/
L ZnCl2, pH 7. 6) for 45 min, followed by a 42 hour incubation in
a buffer containing 50 mmol/L Tris-HCl, 5 mmol/CaCl2,
1 mmol/L ZnCl2, 0. 02% Brij-35, pH 7.6. Gels were finally
stained with Coomassie blue, and images were captured with a gel
scanner. The clear zone on a dark background represented
enzyme activity. Quantitation of bands was performed by
densitometry.
ELISA
Gremlin expression levels in culture medium were measured by
a commercial ELISA kit (Adlitteram Diagnostic Laboratories,
USA) according to the manufacturer’s instructions. The absor-
bance was measured at 492 nm using a micro plate reader (Model
680, Bio-Rad). The results were expressed in nanograms per
milliliter according to the calibration curve obtained with serial
dilutions of a known quantity of Gremlin, and these were then
normalized to the b-actin content of the corresponding tissues.
The procedure was performed three times for each sample.
Terminal Deoxynucleotidyl Transferase (TdT)-mediated
dUTP Nick-end Labeling (TUNEL)
Measurement of apoptotic cells was performed using terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end
labeling (TUNEL) with the in situ Apoptosis Detection Kit
(Chemicon International, Temecula, CA, USA). Briefly, depar-
affinized sections of mouse kidney were digested with proteinase K
solution (Gibco BRL) (20 mg/ml) for 20 minutes at room
temperature. Slides were rinsed in water and treated with 0.3%
H2O2 for 10 minutes at room temperature. Test slides were
incubated in terminal deoxytransferase (TdT) with biotin-dUTP
for 1 hour at 37uC. Slides were washed in water, incubated with
strepavidin-horseradish peroxidase complex for 30 minutes at
room temperature, and detected with DAB (3-amino-9-ethylcar-
bazole) solution (Sigma) for 10 minutes. The numbers of TUNEL
positive cells were counted in 50 glomeruli and in 10
4 mm
2
tubulointerstitial area.
Immunoprecipitation
Mouse mesangial cells were lysed in RIPA buffer (20 mM Tris-
HCl, pH 7.4, 100 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, and
1% Triton X-100) with protease inhibitors. The lysates were
centrifuged at 12,000 g for 30 minutes at 4uC, and the
supernatants were incubated with preimmune sera and protein
A-Sepharose (Amersham Biosciences, GE Healthcare, Uppsala,
Sweden). Immunoprecipitations were performed by adding 10 ml
of rabbit antibodies against mouse Gremlin or BMP-7 (1:100,
Santa Cruz) and 80 ml of protein-A Sepharose to 0.5 ml of
supernatants. Normal rabbit IgG was used as a negative control.
They were incubated overnight at 4uC on a rocking platform. The
immunoprecipitated complexes were dissolved in a gel-loading
buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol,
100 mM DTT, and 0.1% bromophenol blue), subjected to
SDS/PAGE under reducing conditions, and electroblotted onto
Hybond P PVDF membranes (Amersham Biosciences, Piscat-
away, NJ). The membranes were immunoblotted with specific
antibodies against BMP-7 or Gremlin (1:1000) overnight at 4uC
and then with the secondary antibodies conjugated to horseradish
peroxidase (1:20000). Finally, the membranes were immersed in
ECL Plus Western Blotting Detection Reagent (Amersham) and
exposed to Hyperfilm ECL (Amersham).
Statistical Evaluation
Data are presented as mean 6 standard deviation (SD).
Statistical analysis was performed by one-way ANOVA with
Fisher t. P value of ,0.05 was considered significant. The data
were analyzed with Dr. SPSS II for Windows release 11.0.1J.
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